Acurx Pharmaceuticals在亚特兰大美国疾病协会提交了伊贝扎普尔司他临床研究项目的数据

Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), is a late-stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections. It announced today that a presentation was given by Michael Silverman, MD, FACP, Acurx's Medical Director, and Kevin Garey, PharmD, MS, FIDSA, Professor and Chair, University of Houston College of Pharmacy, Principal Investigator for microbiology and microbiome aspects of the ibezapolstat clinical trial program at the Infectious Diseases Society of America (IDSA) IDWeek™ 2025 Scientific Conference held on October 19-22, 2025 in Atlanta, GA.